BRIEF-CSL's unit says ‍new phase III study shows significantly greater efficacy in children 6-24 months who receive AQIV​

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.